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Background
Pulmonary fibrosis (PF) is ani n c r e a s i n gc a u s eo fm o r -
bidity and mortality with five million people affected
worldwide and a median survival time of less than three
years. Effective anti-fibrotic agents for PF are currently
lacking. The majority of patients with PF develop pul-
monary hypertension (PH) and right heart failure.
Impaired production of endogenous nitric oxide (NO)
plays an important role in the pathogenesis of PF-asso-
ciated PH. The NO signaling pathway involves activa-
tion of soluble guanylate cyclase (sGC) with subsequent
generation of cGMP. We hypothesized that sGC might
be involved in the pathogenesis of PF and that the NO-
independent stimulation of sGC might attenuate PH
and fibrotic changes in a clinically relevant mouse
model of PF.
Materials and methods
Male C57/BL6 mice (10-12 wks) were anesthetized,
intubated, and subjected to intratracheal administration
of bleomycin (0.5 U/kg) or saline. The animals were
randomly assigned to gavage-feeding with the sGC sti-
mulator riociguat (1, 3 or 10 mg/kg/day), the phospho-
diesterase 5 (PDE5) inhibitor sildenafil (100 mg/kg/day),
a combination of riociguat (1 mg/kg/day) and sildenafil
(100 mg/kg/day), or vehicle alone for two weeks. There-
after, the mice underwent transthoracic echocardio-
graphic and invasive hemodynamic measurements.
Hearts, lungs and blood were harvested. Two indepen-
dent pathologists blindly measured a surface area
involved by fibrosis and inflammation in hematoxylin
and eosin stained lung sections.
Results
Bleomycin-induced PH (an increase in the right ventri-
c l es y s t o l i cp r e s s u r ea n dad e c r e a s ei nt h ep u l m o n a r y
acceleration time/ejection time ratio) and the right ven-
tricular hypertrophy were attenuated by riociguat and
the combination of riociguat and sildenafil to a greater
extent than by sildenafil alone. In the vehicle-treated
mice, fibrosis and inflammation diffusely involved lung
parenchyma. Riociguat and the combination of riociguat
and sildenafil but not sildenafil alone markedly amelio-
rated PF and inflammation that was mainly confined to
subpleural areas and/or peripheral lung in a patchy dis-
tribution. Riociguat increased plasma cGMP concentra-
tion and also reduced mortality.
Conclusion
Pharmacological stimulation of sGC with riociguat
attenuates PF, PH, right ventricular hypertrophy and
mortality in the bleomycin-exposed mice. This therapeu-
tic approach appears to be superior to treatment with
PDE5 inhibitor sildenafil. This is consistent with the
mode of action: riociguat increases sGC activity in the
absence of NO and also sensitizes sGC to low levels of
endogenous NO, while PDE5 inhibitors prevent the
degradation of cGMP and thus rely on a sufficient
upstream input of NO. Stimulation of sGC might repre-
sent a new modality for treating PF and related
conditions.
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